Min-Tz Weng

Min-Tz Weng

Auto-generated profile, based on publicly available information

Min-Tz Weng

School of Pharmacy and Pharmaceutical Sciences, The University of Queensland , Brisbane, Queensland 4102

Research Focus & Metrics

Academic Career Length

5Years (2022-Present)

(Calculated once Scilit publication data is synced: current year − year of first publication + 1)

Representative Publications

View All Publications
15 July 2022 in Journal of Pharmacy Practice and Research
Verified
Journal Article
Open access
Kathryn SteadmanKathryn Steadman
Kathryn Steadman
MWMin‐Tz Weng
Min‐Tz Weng
MMMarwa A. Malouh
Marwa A. Malouh
KSKeli Symons
Keli Symons
JCJulie Cichero
Julie Cichero
Background: This study characterises commercially available oral liquid medications in terms of thickness and textural suitability for safe swallowing by patients with dysphagia for inclusion in the fourth edition of Don't Rush to Crush (DRTC), published by the Society of Hospital Pharmacists of Australia.Aim: This study had two aims. The first was to use the International Dysphagia Diet Standardisation Initiative (IDDSI) testing methods to evaluate and document the thickness and textural properties of commercially available liquid medications in Australia to be included in the fourth edition of DRTC. The second aim was to determine the volume of oral liquids that could be mixed into medication lubricants while maintaining the lubricant's IDDSI classification.Methods: A total of 121 different oral liquid medications were assessed for flow through a syringe and consistency on a fork according to the IDDSI framework to classify them as Level 0 (Thin), Level 1 (Slightly Thick), Level 2 (Mildly Thick), Level 3 (Moderately Thick), or Level 4 (Extremely Thick).Results: The 121 liquid medications were classified as Level 0 (n = 47, 39%), Level 1 (n = 20, 16%) or Level 2 (n = 54, 45%). Although 18 (15%) of the liquids appeared to be thicker than Level 2 according to the IDDSI flow test, the fork drip test clearly identified them as thinner than Level 3. We considered thickening low‐volume doses using an IDDSI Level 4 medication lubricant; for 97% (n = 112) of 115 oral liquid medications it was possible to incorporate 2.5 mL within two pumps (10 g) of Gloup Forte (vanilla flavour) and retain the IDDSI Level 4 classification.Conclusion: Commercially available oral liquids are classified as IDDSI Level 0, 1, or 2. While they present no problem to healthy people, most patients with dysphagia are unlikely to safely swallow these fluids. Evaluation of the swallowing function of dysphagic patients prior to use of oral medications is essential.

23 February 2026 in Nicotine & Tobacco Research
Verified
Journal Article
Open access
PDF file
MWMin-Tz Weng
Min-Tz Weng
QZQiuda Zheng
Qiuda Zheng
YDYao Deng
Yao Deng
SSShakti Shrestha
Shakti Shrestha
WFWenqing Fan
Wenqing Fan
KSKathryn J Steadman
Kathryn J Steadman
Population-level models predicting tobacco use would benefit from inclusion of an accurate anabasine excretion factor. This study aimed to explore the excretion of anabasine in people who use conventional cigarettes (CCs) and nicotine vaping products (NVPs). A total of 72 participants were enrolled: 22 people who smoked CCs, 20 people who used NVPs, and 30 people who had never smoked or vaped. The quantity of CC and NVP use was documented over a 3-day period. Composite 24-hour urine samples were collected on Day 3 and analysed using LC-MS/MS to quantify nicotine, cotinine (COT), 3-hydroxycotinine (3HC), anabasine and anatabine. The anabasine excretion factor was calculated for urine samples containing anabasine. Nicotine exposure, as the molar sum of nicotine and its metabolites (COT and 3HC) was higher for the NVP group compared to the CC group (p = 0.0460). Anabasine concentrations were low in urine of the NVP group but the difference from the CC group did not reach statistical significance (p = 0.0646). Data from 19 individuals in the CC group was used to calculate anabasine excretion factor, giving a value of 9.02%. The excretion factor for anabasine was calculated from 24-hour urine samples for 19 individuals who smoked cigarettes, providing a preliminary estimate that may be incorporated into predictive modelling for population-level tobacco product use. Given the small sample size of this study, future research with larger cohorts is required to provide more reliable estimates.

30 June 2024 in Health Sciences Review
Verified
Journal Article
Open access
MWMin-Tz Weng
Min-Tz Weng
ARAngela Ratsch
Angela Ratsch
JMJared A Miles
Jared A Miles
Qiuda ZhengQiuda Zheng
Qiuda Zheng
KSKathryn J Steadman
Kathryn J Steadman

8 May 2026 in SSRN Electronic Journal
Verified
Preprint
Open access
ARAngela Ratsch
Angela Ratsch
EBElizabeth Burmeister
Elizabeth Burmeister
MWMin-Tz Weng
Min-Tz Weng
Kathryn SteadmanKathryn Steadman
Kathryn Steadman
JMJared A Miles
Jared A Miles
Qiuda ZhengQiuda Zheng
Qiuda Zheng
Objectives:Accurate measurement of tobacco, nicotine and cannabis use and exposure during pregnancy is essential for research and clinical care, yet existing perinatal surveillance relies on simplified self‑report that inadequately captures exposure patterns. Biological assays provide objective measurement but are invasive, costly, limited to short detection windows, and impractical for repeated or population‑level use. This study aimed to develop and internally validate the Nicotine, Tobacco and Cannabis Use and Exposure (NOTICE) assessment as a low‑burden, non‑biological behavioural tool for use and exposure during pregnancy.Study Design and Setting:In a longitudinal cohort of Australian First Nations pregnant women, repeated NOTICE assessments were collected across pregnancy alongside exhaled carbon monoxide, saliva cotinine, and urinary free cotinine and total 11-Nor-9-carboxy-Δ⁹-tetrahydrocannabinol (THC‑COOH), with and without creatinine correction. Weekly self‑use and exposure scores were combined into a weighted, standardised composite score. Discriminative validity relative to biochemical reference standards was assessed using receiver operating characteristic analysis. Area under the curve (AUC) estimates with bias‑corrected and accelerated bootstrap confidence intervals clustered by participant were calculated. Population‑averaged associations were examined using generalised estimating equations.Results:The composite NOTICE score demonstrated very high discrimination for tobacco and nicotine exposure relative to creatinine‑corrected cotinine ≥5 ng/mg cr (AUC = 0.99; 95% CI 0.98–1.00) and high discrimination for cannabis exposure relative to creatinine‑corrected THC‑COOH ≥80 ng/mg cr (AUC = 0.92; 95% CI 0.83–1.00). Discrimination was stable across alternative biomarker thresholds and consistently superior to exposure‑only measures. Weekly scores demonstrated better discriminative performance than daily scores.Conclusion:NOTICE is a low-burden behavioural assessment that demonstrates strong criterion-based alignment with established biochemical reference standards for measuring tobacco, nicotine and cannabis use and exposure during pregnancy. By integrating active use and environmental exposure across products and timeframes, the tool supports repeated measurement and surveillance of exposure patterns in settings where routine biological testing is impractical.What is new?Key findingsThis study shows that a structured, non‑biological behavioural measurement framework for assessing tobacco, nicotine and cannabis use and exposure in pregnancy can demonstrate high discriminative validity relative to established biochemical reference standards, including urinary cotinine, THC‑COOH and exhaled carbon monoxide.What this adds to what is knownReliable measurement of tobacco, nicotine and cannabis exposure is fundamental to understanding and addressing pregnancy‑related risk, yet existing perinatal surveillance relies on simplified self‑report that inadequately captures exposure patterns. NOTICE enables comprehensive, structured point‑of‑care measurement of use, environmental exposure, temporal variability and context, providing a low‑burden approach that aligns closely with biochemical markers without the logistical, ethical and financial constraints of routine biological specimen collection.What is the implication, what should change now?Incorporation of the NOTICE assessment into research and clinical practice offers a scalable, sta

7 October 2026 in Heliyon
Verified
Journal Article
Open access
MWMin-Tz Weng
Min-Tz Weng
QZQiuda Zheng
Qiuda Zheng
YDYao Deng
Yao Deng
SSShakti Shrestha
Shakti Shrestha
WFWenqing Fan
Wenqing Fan
Kathryn SteadmanKathryn Steadman
Kathryn Steadman

14 October 2026 in Journal of Clinical Epidemiology
Verified
Journal Article
Open access
EBElizabeth Burmeister
Elizabeth Burmeister
MWMin-Tz Weng
Min-Tz Weng
KSKathryn J. Steadman
Kathryn J. Steadman
JMJared A Miles
Jared A Miles
Qiuda ZhengQiuda Zheng
Qiuda Zheng
ARAngela Ratsch
Angela Ratsch